Results of ALLEVIATE-1 and ALLEVIATE-2 Phase 3 trials of cebranopadol, a first-in-class, dual NOP/MOP receptor agonist for the treatment of acute pain after abdominoplasty and bunionectomy (PainConnect 2026) - Feb 12, 2026 - Pres time: Mar 6, 2026; 01:05 PM - 01:10 PM; Location: Grand Ballroom BC; No abstract available
P3 data • Aesthetic Medicine • Pain
|